CP Weesp, Netherlands

Erik Gout


Average Co-Inventor Count = 9.3

ph-index = 1

Forward Citations = 8(Granted Patents)


Location History:

  • Weesp, NL (2008)
  • CP Weesp, NL (2011)

Company Filing History:


Years Active: 2008-2011

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Erik Gout

Introduction

Erik Gout is a notable inventor based in CP Weesp, Netherlands. He has made significant contributions to the pharmaceutical field, particularly in the development of novel dosage forms and compounds. With a total of 2 patents to his name, Gout's work focuses on treatments for various diseases and disorders.

Latest Patents

Gout's latest patents include "Bifeprunox mesylate maintenance dose compositions and methods for using the same." This patent provides novel pharmaceutical dosage forms designed for maintenance treatment doses, along with methods for their preparation and use in treating and preventing diseases. Another significant patent is for a "Stable crystalline form of bifeprunox mesylate." This invention relates to a stable polymorphic form of the compound 7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate, which is particularly useful in pharmaceutical products for treating psychotic disorders and Parkinson's disease.

Career Highlights

Erik Gout is currently associated with Solvay Pharmaceuticals B.V., where he continues to innovate and contribute to the field of pharmaceuticals. His work has been instrumental in advancing treatment options for patients suffering from complex conditions.

Collaborations

Gout has collaborated with notable colleagues such as Irene Eijgendaal and Gerrit Klein, enhancing the impact of his research and inventions.

Conclusion

Erik Gout's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare through effective treatments. His patents reflect a deep understanding of the complexities involved in drug formulation and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…